Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AMGN Amgen	$295.22 -0.7%	$281.33	$253.30 ▼ $346.85	$158.74B	0.51	2.82 million shs	2.19 million shs
GILD Gilead Sciences	$109.98 -1.8%	$105.67	$62.69 ▼ $119.96	$136.81B	0.29	7.74 million shs	8.15 million shs
INFI Infinity Pharmaceuticals		$0.07	$0.01 ▼ $0.01	$726K	1.63	2.58 million shs	2.48 million shs
MTEM Molecular Templates		$0.00	$0.00 ▼ $1.59	$1K	1.53	4.91 million shs	N/A

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AMGN Amgen	0.00%	+1.68%	+8.66%	-5.89%	-1.95%
GILD Gilead Sciences	0.00%	-2.21%	+9.61%	-1.31%	+70.94%
INFI Infinity Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	0.00%
MTEM Molecular Templates	0.00%	0.00%	0.00%	0.00%	-99.99%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AMGN Amgen	4.4507 of 5 stars	2.2	4.0	3.3	3.9	3.5	2.5	0.6
GILD Gilead Sciences	4.9076 of 5 stars	2.4	5.0	4.2	4.1	3.9	2.5	1.9
INFI Infinity Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AMGN Amgen	2.38	Hold	$309.22	4.74% Upside
GILD Gilead Sciences	2.78	Moderate Buy	$110.55	0.51% Upside
INFI Infinity Pharmaceuticals	0.00	N/A	N/A	N/A
MTEM Molecular Templates	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest INFI, MTEM, AMGN, and GILD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/20/2025	AMGN Amgen	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Neutral	$288.00
5/16/2025	AMGN Amgen	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$329.00 ➝ $328.00
5/8/2025	AMGN Amgen	Erste Group Bank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/7/2025	AMGN Amgen	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$235.00 ➝ $280.00
5/2/2025	AMGN Amgen	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$319.00 ➝ $315.00
5/2/2025	AMGN Amgen	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight
5/2/2025	AMGN Amgen	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$324.00 ➝ $320.00
4/25/2025	GILD Gilead Sciences	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$130.00 ➝ $135.00
4/25/2025	GILD Gilead Sciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$132.00 ➝ $125.00
4/25/2025	GILD Gilead Sciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AMGN Amgen	$34.13B	4.65	$29.58 per share	9.98	$10.93 per share	27.01
GILD Gilead Sciences	$28.74B	4.76	$8.69 per share	12.66	$15.44 per share	7.12
INFI Infinity Pharmaceuticals	$2.59M	0.00	N/A	N/A	($0.21) per share	0.00
MTEM Molecular Templates	$23.48M	0.00	N/A	N/A	$0.78 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AMGN Amgen	$4.09B	$10.96	39.10	13.80	2.63	12.24%	176.32%	11.71%	8/5/2025 (Estimated)
GILD Gilead Sciences	$480M	$4.75	297.24	13.56	0.71	1.67%	31.63%	10.38%	8/6/2025 (Estimated)
INFI Infinity Pharmaceuticals	-$44.37M	-$0.46	N/A	N/A	N/A	-1,593.93%	N/A	-113.02%	N/A
MTEM Molecular Templates	-$8.12M	-$2.70	N/A	N/A	N/A	-61.35%	-260.50%	-46.90%	N/A

Latest INFI, MTEM, AMGN, and GILD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
5/1/2025	Q1 2025	AMGN Amgen	$4.18	$4.90	+$0.72	$3.20	$8.05 billion	$8.15 billion
4/24/2025	Q1 2025	GILD Gilead Sciences	$1.77	$1.81	+$0.04	$1.04	$6.77 billion	$6.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AMGN Amgen	$9.52	3.22%	N/A	86.86%	14 Years
GILD Gilead Sciences	$3.16	2.87%	N/A	66.53%	10 Years
INFI Infinity Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTEM Molecular Templates	N/A	N/A	N/A	N/A	N/A

Latest INFI, MTEM, AMGN, and GILD Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
4/22/2025	GILD Gilead Sciences	quarterly	$0.79	3%	6/13/2025	6/13/2025	6/27/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AMGN Amgen	9.62	1.26	0.95
GILD Gilead Sciences	1.24	1.50	1.20
INFI Infinity Pharmaceuticals	N/A	1.65	1.65
MTEM Molecular Templates	N/A	1.56	1.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AMGN Amgen	76.50%
GILD Gilead Sciences	83.67%
INFI Infinity Pharmaceuticals	22.14%
MTEM Molecular Templates	95.47%

Insider Ownership

Company	Insider Ownership
AMGN Amgen	0.76%
GILD Gilead Sciences	0.27%
INFI Infinity Pharmaceuticals	9.81%
MTEM Molecular Templates	13.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AMGN Amgen	25,200	537.71 million	533.50 million	Optionable
GILD Gilead Sciences	17,000	1.24 billion	1.24 billion	Optionable
INFI Infinity Pharmaceuticals	30	90.76 million	81.86 million	Optionable
MTEM Molecular Templates	260	6.58 million	5.67 million	No Data

INFI, MTEM, AMGN, and GILD Headlines

Recent News About These Companies

Molecular Templates enters bankruptcy, secures DIP financing

April 26, 2025 | investing.com

What’s Fueling Molecular Templates Inc (MTEM) Stock’s -91.30% Loss Below Its 200-Day SMA?

December 26, 2024 | bovnews.com

Molecular Templates Inc (MTEM) Stock: More Resilient Than It Appears

December 23, 2024 | bovnews.com

Nasdaq to file Form 25-NSE with SEC to delist Molecular Templates

December 20, 2024 | markets.businessinsider.com

Molecular Templates, Inc. Faces Delisting from Nasdaq Due to Compliance Issues

December 19, 2024 | quiverquant.com

Molecular Templates Announces Notice of Delisting and Failure to Satisfy Continued Listing Rules

December 19, 2024 | globenewswire.com

Molecular Templates Inc (MTEM) Stock Settles at $0.42: What’s Contributing to This Price Point?

December 10, 2024 | bovnews.com

Molecular Templates Inc (MTEM) Stock Price Reaches $0.34: What Factors Are Influencing This Level?

December 5, 2024 | bovnews.com

Molecular Templates Announces Key Leadership Transition

December 4, 2024 | markets.businessinsider.com

Molecular Templates, Inc. Receives Nasdaq Deficiency Notification for Reporting and Bid Price Compliance

December 2, 2024 | quiverquant.com

Molecular Templates Announces Receipt of Expected Notification of Deficiency from Nasdaq Related to Delayed filing of Quarterly Report on Form 10-Q and Failure to Meet Bid Price Requirements

December 2, 2024 | globenewswire.com

Molecular Templates Inc (MTEM) Stock Settles at $0.37: What’s Contributing to This Price Point?

November 29, 2024 | bovnews.com

Why Did BofA Securities Give Molecular Templates Inc (MTEM) Stock Buy Rating?

November 27, 2024 | bovnews.com

Molecular Templates Inc (MTEM) Stock Sees Market Value Hit $2.21 million: What Are the Implications?

November 26, 2024 | bovnews.com

Molecular Templates Inc (MTEM) Stock: More Strategic Than Meets the Eye

November 23, 2024 | bovnews.com

Target N. V. Biotech Sells 1,279,820 Shares of Molecular Templates, Inc. (NASDAQ:MTEM) Stock

November 19, 2024 | insidertrades.com

Why Did Molecular Templates Inc (MTEM) Stock See -69.97% Plunge in the Last 90 Days?

November 19, 2024 | bovnews.com

Molecular Templates Inc (MTEM) Stock: Surpassing Expectations in the Market?

November 16, 2024 | bovnews.com

“Astonishing” – Scientists Unveil First Blueprint of the Most Complex Molecular Machine in Human Biology

November 10, 2024 | scitechdaily.com

Why Did Molecular Templates Inc (MTEM) Stock See -44.44% Plunge in the Last 90 Days?

October 22, 2024 | bovnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

INFI, MTEM, AMGN, and GILD Company Descriptions

Amgen NASDAQ:AMGN

$295.22 -2.07 (-0.70%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$294.75 -0.47 (-0.16%)

As of 06/13/2025 07:59 PM Eastern

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

Gilead Sciences NASDAQ:GILD

$109.98 -2.07 (-1.85%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$110.03 +0.05 (+0.05%)

As of 06/13/2025 07:28 PM Eastern

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Molecular Templates NASDAQ:MTEM

Molecular Templates, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other serious diseases in the United States. The company develops therapies through its proprietary biologic drug platform technology (ETB). It is also developing MT- 8421, an ETB candidate that is in Phase I clinical trial for the treatment of dismantling TME through direct cell-kill of tumor and immune cell; MT-0169, which is in Phase I clinical trial to treat relapsed/refractory multiple myeloma; and MT-6402 in that is in Phase I clinical trial for relapsed/refractory patients with PD-L1 expressing tumors. The company has a collaboration agreement with Bristol Myers Squibb to discover and develop novel products containing ETBs directed to multiple targets. Molecular Templates, Inc. was founded in 2001 and is headquartered in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time